Cisplatin
- Atc Codes:L01XA01
- CAS Codes:15663-27-1
- PHARMGKB ID:15663-27-1
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Induces
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Cisplatin; Belgium: Cisplatine, Platosin; Bulgaria: Cisplatin, Sinplatin; Cyprus: Cisplatin; Czech Republic: Cisplatin, Platidiam, Platosin; Denmark: Cisplatin; Estonia: Cisplatin; Finland: Cisplatin; France: Cisplatine, Cisplatyl; Germany: Cis-GRY, Cisplatin, Platinol, Ribocis; Greece: Cisplatin, Cisplatyl, Oncoplat, Platamine; Hungary: Cisplatin, Platidiam; Ireland: Cisplatin; Italy: Cisplatin, Platamine; Latvia: Cisplatin, Cytoplatin; Lithuania: Cisplatin; Luxembourg: Cisplatine, Cisplatinum, Platistine; Malta: Cisplatin; Netherlands: Cisplatine, Platosin; Poland: Blastolem, Cisplatin, Platamine, Platidiam; Portugal: Cisplatina; Romania: Cisplatin, Sinplatin; Slovakia: Cisplatin, Platidiam, Platis; Slovenia: Cisplatin, Platinex; Spain: Cisplatino; Sweden: Cisplatin; UK: Cisplatin.
North America
Canada: Cisplatin; USA: Cisplatin, Platinol.
Latin America
Argentina: Cisplatino, Elvecis, Platino II, Sicatem; Brazil: Cisplatex, Citoplax, C-Platin-Cisplatina, Incel, Platiran, Platistine CS, Tecnoplatin; Mexico: Blastolem RU, Noveldexis, Platinol.
Asia
Japan: Briplatin, Cisplamerck, Cisplatin, IA-call, Platosin, Randa.
Drug combinations
Cisplatin and Docetaxel
Cisplatin, Carmustine, and Dacarbazine
Cisplatin, Dacarbazine, and Vinblastine
Cisplatin, Docetaxel, and Fluorouracil
Cisplatin, Docetaxel, and Trastuzumab
Cisplatin, Aldesleukin, Dacarbazine, and Interferon Alpha-2b
Cisplatin, Carmustine, Dacarbazine, and Tamoxifen
Chemistry
Cisplatin: Cl~2~H~6~N~2~Pt. Mw: 300.05. (1) Platinum, diamminedichloro-, (SP-4-2)-; (2) cis-Diamminedichloroplatinum. CAS-15663-27-1 (1977).
Pharmacologic Category
Other Antineoplastic Agents; Platinum Compounds. (ATC-Code: L01XA01).
Mechanism of action
Forms platinum complexes that bind to specific DNA base sequences, producing intrastrand and interstrand DNA cross-links, which are thought to inhibit DNA replication, transcription, and ultimately cell division. Denatures the double helix. Covalently binds to DNA bases and disrupts DNA function. May also bind to proteins. Cisplatin can also bind two adjacent guanines on the same strand of DNA producing intrastrand cross-linking and breakage. Cycle-phase nonspecific. Exhibits immunosuppressive, radiosensitizing, and antimicrobial properties. Possible cross-resistance with carboplatin.
Therapeutic use
Bladder cancer. Testicular cancer. Ovarian cancer.
Pregnancy and lactiation implications
Teratogenicity and embryotoxicity in animal studies. There are no adequate studies in pregnant women. May be toxic to fetal urogenital tract. Enters breast milk.
Unlabeled use
Head and neck, breast, gastric, lung, esophageal, cervical, prostate and small cell lung cancer. Hodgkin’s and non-Hodgkin lymphoma. Neuroblastoma. Sarcomas, myeloma, melanoma, mesothelioma, and osteosarcoma.
Contraindications
Hypersensitivity to cisplatin, other platinum-containing compounds, or any component of the formulation (anaphylactic-like reactions reported). Pre-existing renal insufficiency. Myelosuppression. Hearing impairment. Pregnancy.
Warnings and precautions
Anaphylactic-like reactions reported. Myelosuppression, nausea, and vomiting are dose-related toxicities. Severe and possibly irreversible neuropathies may occur with higher than recommended doses or more frequent regimen. Ototoxicity, especially pronounced in children. Cumulative renal toxicity may be severe. When administered as sequential infusions, taxane derivatives (docetaxel, paclitaxel) should be administered before platinum derivatives (carboplatin, cisplatin). Caution in the elderly (may be more susceptible to nephrotoxicity and peripheral neuropathy).